Two-year retrospective analysis of repeated emergency service admissions in a secondary stage hospital: Diagnosis-based evaluation
Abstract
Objective: This study aims to evaluate the characteristics of repeated emergency department (ED) visits in a secondary care hospital over a two-year period and analyze trends across different diagnostic categories.
Methods: A retrospective analysis was conducted on ED visit data from January 2023 to September 2024. Patient demographics, primary diagnoses, and visit frequencies were examined. Statistical analyses were performed to compare trends between 2023 and 2024, with subgroup analyses based on age and gender.
Results: The repeated visit rate was found to be 25.8% in 2023 and 26.0% in 2024, consistent with existing literature. The most common diagnosis was upper respiratory tract infections (URTI), accounting for 109,067 visits in 2023 and 83,655 visits in 2024, showing a significant decline. In contrast, general medical examinations and gastroenteritis cases increased in 2024 compared to 2023, indicating a potential shift in healthcare-seeking behavior. Myalgia ranked second, with 26,727 cases in 2023 and 21,225 in 2024, predominantly affecting middle-aged women. Falls and soft tissue disorders, ranked third, were more prevalent in male patients, with 24,351 cases in 2023 and 19,616 in 2024. Age-specific trends showed that trauma-related conditions were most common in children (0-10 years), while musculoskeletal and cardiovascular disorders increased with age. Gender distribution analysis indicated that headache and acute cystitis were more frequent in women, whereas…
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.